Barclays keeps Sell rating for Pacific Biosciences stock

Published on 10/08/2026 at 11:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays set a USD 1.25 target under Sell on October 7, 2026. Pacific Biosciences stock stands at EUR 2.43 on October 8, 2026 versus EUR 2.41.

PACB, US69404D1081, Illustration mit AI erstellt.

Pacific Biosciences stock (ISIN US69404D1081) was trading at EUR 2.43 at Lang & Schwarz on October 8, 2026 at 11:15 a.m. CEST, plus 0.83 percent versus the prior close of EUR 2.41. According to Markets Insider on October 7, 2026, Barclays analyst Luke Sergott maintained a Sell rating and set a USD 1.25 price target.

Barclays highlights valuation pressure

The USD 1.25 target is 54.22 percent below the USD 2.72 primary-market price cited for October 7, 2026. The comparison puts the Barclays view below the wider analyst consensus reported by Markets Insider, which showed a Hold rating and a USD 1.90 average target on October 7, 2026.

That target contrast matters because PacBio remains loss-making while it expands its sequencing platform. PacBio reported USD 39.00 million in second-quarter 2026 revenue, USD 44.74 million in GAAP net loss and USD 236.9 million in cash, equivalents and investments.

Revenue mix points to consumables

The second-quarter 2026 revenue mix included USD 20.1 million from consumables, USD 12.8 million from instruments and USD 6.1 million from service and other revenue, according to PacBio. Consumables therefore represented 51.54 percent of the USD 39.00 million quarterly total, making recurring usage a central operating measure.

PacBio also guided to full-year 2026 revenue of USD 155.0 million to USD 165.0 million and a non-GAAP gross-margin range of 35.00 percent to 37.00 percent. The company presentation identified SPRQ-Nx adoption, clinical and commercial realignment, and a future high-throughput platform as priorities for the next 12 to 18 months.

PACB stays inside its yearly range

PACB was last quoted at USD 2.72 on the primary US listing on October 7, 2026, with a 52-week range of USD 1.07 to USD 3.44. Its market capitalization was USD 844.8 million on that date, while the Lang & Schwarz euro quote remained the relevant reference for German investors.

At Lang & Schwarz, Pacific Biosciences stock was trading at EUR 2.43 on October 8, 2026 at 11:15 a.m. CEST, plus 0.83 percent versus the EUR 2.41 prior close of October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Pacific Biosciences stock.